全文获取类型
收费全文 | 25552篇 |
免费 | 1960篇 |
国内免费 | 85篇 |
专业分类
耳鼻咽喉 | 419篇 |
儿科学 | 929篇 |
妇产科学 | 398篇 |
基础医学 | 2630篇 |
口腔科学 | 552篇 |
临床医学 | 2288篇 |
内科学 | 5621篇 |
皮肤病学 | 584篇 |
神经病学 | 1361篇 |
特种医学 | 1177篇 |
外国民族医学 | 1篇 |
外科学 | 4811篇 |
综合类 | 359篇 |
一般理论 | 16篇 |
预防医学 | 1286篇 |
眼科学 | 956篇 |
药学 | 2209篇 |
中国医学 | 45篇 |
肿瘤学 | 1955篇 |
出版年
2023年 | 212篇 |
2022年 | 379篇 |
2021年 | 1056篇 |
2020年 | 509篇 |
2019年 | 865篇 |
2018年 | 1007篇 |
2017年 | 644篇 |
2016年 | 694篇 |
2015年 | 743篇 |
2014年 | 1080篇 |
2013年 | 1254篇 |
2012年 | 1891篇 |
2011年 | 1838篇 |
2010年 | 949篇 |
2009年 | 893篇 |
2008年 | 1396篇 |
2007年 | 1347篇 |
2006年 | 1213篇 |
2005年 | 1053篇 |
2004年 | 963篇 |
2003年 | 830篇 |
2002年 | 713篇 |
2001年 | 627篇 |
2000年 | 598篇 |
1999年 | 530篇 |
1998年 | 176篇 |
1997年 | 155篇 |
1996年 | 162篇 |
1995年 | 153篇 |
1994年 | 123篇 |
1993年 | 110篇 |
1992年 | 304篇 |
1991年 | 306篇 |
1990年 | 267篇 |
1989年 | 226篇 |
1988年 | 224篇 |
1987年 | 232篇 |
1986年 | 204篇 |
1985年 | 193篇 |
1984年 | 125篇 |
1983年 | 138篇 |
1982年 | 94篇 |
1981年 | 77篇 |
1980年 | 69篇 |
1979年 | 135篇 |
1978年 | 78篇 |
1977年 | 73篇 |
1975年 | 66篇 |
1974年 | 72篇 |
1973年 | 91篇 |
排序方式: 共有10000条查询结果,搜索用时 296 毫秒
981.
Jay N. Patel Jonathon M. Spanyer Langan S. Smith Jiapeng Huang Madhusudhan R. Yakkanti Arthur L. Malkani 《The Journal of arthroplasty》2014
The purpose of this study was to compare the efficacy of topical Tranexamic Acid (TXA) versus Intravenous (IV) Tranexamic Acid for reduction of blood loss following primary total knee arthroplasty (TKA). This prospective randomized study involved 89 patients comparing topical administration of 2.0 g TXA, versus IV administration of 10 mg/kg. There were no differences between the two groups with regard to patient demographics or perioperative function. The primary outcome measure, perioperative change in hemoglobin level, showed a decrease of 3.06 ± 1.02 in the IV group and 3.42 ± 1.07 in the topical group (P = 0.108). There were no statistical differences between the groups in preoperative hemoglobin level, lowest postoperative hemoglobin level, or total drain output. One patient in the topical group required blood transfusion (P = 0.342). Based on our study, topical Tranexamic Acid has similar efficacy to IV Tranexamic Acid for TKA patients. 相似文献
982.
M.R. Laftavi O. Pankewycz A. Gruessner Murray Brian R. Kohli L. Feng M. Said R. Sharma S. Patel 《Transplantation proceedings》2014
Background
Currently, the long-term advantages of having a pancreas transplantation (PT) are debated, particularly in patients receiving pancreas after kidney (PAK) allografts. The United Network for Organ Sharing (UNOS) requires that a transplant center perform a minimum number of PT per year to remain an active PT center. The long-term outcomes and challenges of PAK in small pancreas transplant centers are not well studied.Methods
In this retrospective analysis, we report short- and long-term outcomes in a small center performing 2–9 PT annually.Results
Forty-eight PT (25 simultaneous pancreas and kidney transplantation [SPK], 23 PAK) were performed in our center. Donor and recipient demographics were similar in both groups. All suitable local donors were used for SPK. All organs for PAK transplantation were imported from other UNOS regions. Mean follow-up was 61 ± 46 and 74 ± 46 months for SPK and PAK, respectively. Patient and graft survival rates were similar in SPK and PAK groups and better than the reported national average. Four patients (11%) died (1 due to trauma, 1 brain lymphoma, 1 ruptured aneurysm; and 1 unknown cause). Two patients (4%; 1 SPK, 1 PAK) lost their grafts because of thrombosis on postoperative days 3 and 5 in 2002. No graft thrombosis occurred since 2002. Seven patients (15%) required reoperation (4 for bleeding, 2 anastomotic leaks, 1 small bowel perforation). Two patients (4%) developed post-transplantation lymphoproliferative disease. Five patients (11%) experienced cytomegalovirus antigenemia which responded well to antiviral therapy.Conclusions
Compared with outcomes for diabetic patients on dialysis, current SPK and PAK short- and long-term results are favorable even in a small PT center. Therefore, unless there is a contraindication, PT should be offered to all type 1 diabetic patients with end-stage renal disease at the time of kidney transplantation or afterward. 相似文献983.
984.
985.
J George K Grebenik N Patel D Cranston S Westaby 《Annals of the Royal College of Surgeons of England》2014,96(6):e18-e19
The surgical treatment of advanced renal cancers is challenging. Renal cell carcinoma is interesting in that it invades the vasculature and can extend up as far as the right atrium. Extension of tumour thrombus into the right atrium represents level IV disease, according to Robson staging. Transoesophageal echocardiography is useful for diagnostic purposes. It is also of great value for intraoperative cardiac monitoring and to confirm the extent of vascular involvement. 相似文献
986.
R Patel P Chana J Armstrong R Lawrence 《Annals of the Royal College of Surgeons of England》2014,96(6):e8-e9
We describe a rare case of a leiomyosarcoma in the inguinal canal in a patient presenting clinically with an inguinal hernia. The clinical details, histological findings and surgical management are reviewed. 相似文献
987.
M. Rafiei M. Kittleson J. Patel A. Osborne D. Chang L. Czer N. Reinsmoen F. Esmailian J. Kobashigawa 《Transplantation proceedings》2014,46(10):3570-3574
BackgroundRabbit anti-thymocyte globulin (RATG) has been used as induction therapy in heart transplantation. RATG is polyclonal and has been postulated to have anti-humoral properties by preventing the production of circulating antibodies after heart transplant. Thus, we reviewed our patients who received RATG induction therapy and compared them with those who did not receive therapy for post-transplant de novo antibody production.MethodsBetween January 1, 2006, and January 1, 2013, we assessed 196 non-sensitized heart transplant recipients and divided them into those who received 3 to 5 days of RATG induction therapy mostly due to renal insufficiency (n = 35) versus patients who did not receive therapy (n = 161). All patients were given tacrolimus, mycophenolate mofetil, and corticosteroids. Post-transplant circulating antibodies were routinely monitored at 1, 3, 6, and 12 months after heart transplantation; 1-year and 3-year end points were assessed.ResultsThe RATG-treated group had a significantly higher 12-month freedom from de novo antibody production compared with the patients who did not receive RATG induction (89% vs 71%, log-rank P = .043); however there was no significant difference for 12-month freedom from de novo donor-specific antibody production (91% vs 88%, log-rank P = .541). Treated rejection rates in the first-year were comparable in both groups; 3-year actuarial survival, freedom from cardiac allograft vasculopathy, and freedom from non-fatal major adverse cardiac events were also similar between both groups.ConclusionsRATG induction therapy appears to reduce the production of de novo circulating antibodies in non-sensitized patients during the first year after heart transplantation. Although there were no short-term clinical differences between groups, there were imbalances in group characteristics and relatively short follow-up, which are limitations to this study. A randomized, clinical trial with longer follow-up in a larger cohort of patients is warranted. 相似文献
988.
989.
Steven G. Coca Amit X. Garg Heather Thiessen-Philbrook Jay L. Koyner Uptal D. Patel Harlan M. Krumholz Michael G. Shlipak Chirag R. Parikh 《Journal of the American Society of Nephrology : JASN》2014,25(5):1063-1071
Urinary biomarkers of AKI provide prognostic value for in-hospital outcomes, but little is known about their association with longer-term mortality after surgery. We sought to assess the association between kidney injury biomarkers and all-cause mortality in an international, multicenter, prospective long-term follow-up study from six clinical centers in the United States and Canada composed of 1199 adults who underwent cardiac surgery between 2007 and 2009 and were enrolled in the Translational Research in Biomarker Endpoints in AKI cohort. On postoperative days 1–3, we measured the following five urinary biomarkers: neutrophil gelatinase-associated lipocalin, IL-18, kidney injury molecule-1 (KIM-1), liver fatty acid binding protein, and albumin. During a median follow-up of 3.0 years (interquartile range, 2.2–3.6 years), 139 participants died (55 deaths per 1000 person-years). Among patients with clinical AKI, the highest tertiles of peak urinary neutrophil gelatinase-associated lipocalin, IL-18, KIM-1, liver fatty acid binding protein, and albumin associated independently with a 2.0- to 3.2-fold increased risk for mortality compared with the lowest tertiles. In patients without clinical AKI, the highest tertiles of peak IL-18 and KIM-1 also associated independently with long-term mortality (adjusted hazard ratios [95% confidence intervals] of 1.2 [1.0 to 1.5] and 1.8 [1.4 to 2.3] for IL-18 and KIM-1, respectively), and yielded continuous net reclassification improvements of 0.26 and 0.37, respectively, for the prediction of 3-year mortality. In conclusion, urinary biomarkers of kidney injury, particularly IL-18 and KIM-1, in the immediate postoperative period provide additional prognostic information for 3-year mortality risk in patients with and without clinical AKI.In many studies, the development of AKI, defined by acute changes in serum creatinine, associates with a higher risk of long-term mortality.1,2 Acute changes in serum creatinine, however, may not fully reflect the severity of kidney injury due to the influence of age, sex, muscle mass, changes in hydration, nutritional status, and medications on creatinine kinetics. Moreover, serum creatinine may abruptly rise in hospitalized settings due to functional processes such as altered hemodynamics, without any true nephron damage. Several urinary biomarkers of structural kidney injury have been investigated in human cohorts in an effort to identify AKI earlier, improve the diagnosis of AKI, and to aid in risk stratification.3 It is largely unknown, however, whether kidney injury biomarkers associate with long-term outcomes, including mortality, and whether these biomarkers add useful prognostic information beyond the standard measure to detect AKI (e.g., peak change in serum creatinine). Some data suggest that “subclinical AKI,” as evidenced by elevations in urinary kidney injury biomarkers in the absence of a rise in serum creatinine, associates with worse in-hospital clinical outcomes.4 Few studies have examined whether kidney injury biomarkers associate with long-term mortality after hospital discharge.5To address the current knowledge gaps, we conducted this study to characterize the association between kidney injury biomarkers and long-term mortality and to assess whether these biomarkers provide any incremental prognostic information for long-term mortality beyond that of serum creatinine changes and other clinical variables. 相似文献
990.